Distinctive pseudopalisaded histiocytic hyperplasia characterizes the transition of exudative to proliferative phase of diffuse alveolar damage in patients dying of COVID-19

• DOI: 10.1016/j.humpath.2021.06.008
• Publication Date: 2021-07-14T15:38:39Z
• Authors: Michael Kritselis; Ilyas Yambayev; Andrey Prilutskiy; Artem Shevtsov; Charitha Vadlamudi; Hanqiao Zheng; Murad Elsadwai; Lina Ma; Emily Aniskovich; Yachana Kataria; Sara Higgins; Carmen Sarita-Reyes; Tao Zuo; Qing Zhao; Karen Quillen; Eric J. Burks
• Keywords: Adult; Aged, 80 and over; Male; 0301 basic medicine; Hyperplasia; COVID-19; Histiocytes; Original Contribution; Middle Aged; 3. Good health; Pulmonary Alveoli; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; Lung; Aged; Cell Proliferation

Severe COVID-19 results in a glucocorticoid responsive form of acute respiratory distress (ARDS)/diffuse alveolar damage (DAD). Herein we compare the immunopathology of lung tissue procured at autopsy in patients dying of SARS-CoV-2 with those dying of DAD prior to the COVID-19 pandemic. Autopsy gross and microscopic features stratified by duration of illness in twelve patients who tested positive for SARS-CoV-2 viral RNA, as well as seven patients dying of DAD prior to the COVID-19 pandemic were evaluated with multiplex (5-plex: CD4, CD8, CD68, CD20, AE1/AE3) and SARS-CoV immunohistochemistry to characterize the immunopathologic stages of DAD. We observed a distinctive pseudopalisaded histiocytic hyperplasia interposed between the exudative and proliferative phase of COVID-19 associated DAD, which was most pronounced at the fourth week from symptom onset. Pulmonary macrothrombi were seen predominantly in cases with pseudopalisaded histiocytic hyperplasia and/or proliferative phase DAD. Neither pseudopalisaded histiocytic hyperplasia nor pulmonary macrothrombi was seen in non-COVID-19 DAD cases, whereas microthrombi were common in DAD regardless of etiology. The inflammatory pattern of pseudopalisaded histiocytic hyperplasia may represent the distinctive immunopathology associated with the dexamethasone responsive form of DAD seen in severe COVID-19.